Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Fiche publication
Date publication
juin 2017
Journal
European journal of endocrinology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TAILLANDIER Luc
Tous les auteurs :
Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, Desailloud R, Jublanc C, Lebrun-Frenay C, Sadoul JL, Taillandier L, Batisse-Lignier M, Bonnet F, Bourcigaux N, Bresson D, Chabre O, Chanson P, Garcia C, Haissaguerre M, Reznik Y, Borot S, Villa C, Vasiljevic A, Gaillard S, Jouanneau E, Assié G, Raverot G
Lien Pubmed
Résumé
Only few retrospective studies have reported an efficacy rate of temozolomide (TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated patients is rarely evaluated. We therefore aimed to describe the use of TMZ on PT in clinical practice and evaluate the long-term survival.
Mots clés
ACTH-Secreting Pituitary Adenoma, drug therapy, Adult, Antineoplastic Agents, Alkylating, therapeutic use, Carcinoma, drug therapy, Chemoradiotherapy, Cohort Studies, Dacarbazine, analogs & derivatives, Drug Resistance, Neoplasm, Female, Follow-Up Studies, France, Humans, Male, Neoplasm Grading, Neoplasm Invasiveness, Neoplasm Recurrence, Local, epidemiology, Pituitary Neoplasms, drug therapy, Practice Patterns, Physicians', Prolactinoma, drug therapy, Retrospective Studies, Survival Analysis, Temozolomide, Tumor Burden, drug effects
Référence
Eur. J. Endocrinol.. 2017 Jun;176(6):769-777